Article Information
History
- December 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- 1Department of Genitourinary Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
- 2Department of Integrated Mathematical Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
- 3Department of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA
- 4Cancer Biology and Evolution Program, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
- ↵*Corresponding Author
Robert A. Gatenby, Department of Radiology, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, Email: Robert.Gatenby{at}moffitt.org)
Author contributions R.A.G., J.S.B., J.Z., and J.J.C. contributed to the development of the evolutionary mathematical models, J.S.B. and J.J.C. performed the computational models, J.Z. conducted the clinical trial, J.S.B. performed the statistical analysis, R.A.G., J.S.B., J.Z., and J.J.C. wrote the manuscript.
Posted December 02, 2021.
Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer
